Safety and efficacy of inhaled interferon-β1a (SNG001) in adults with mild-to-moderate COVID-19: a randomized, controlled, phase II trial

By sjmartinez • October 19, 2023

Jagannathan P, Chew KW, Giganti MJ, Hughes MD, Moser C, Main MJ, Monk PD, Javan AC, Li JZ, Fletcher CV, McCarthy C, Wohl DA, Daar ES, Eron JJ, Currier JS, Singh U, Smith DM, Fischer W; ACTIV-2/A5401 Study Team. Safety and efficacy of inhaled interferon-β1a (SNG001) in adults with mild-to-moderate COVID-19: a randomized, controlled, phase II trial. EClinicalMedicine. 2023 Oct 6;65:102250. doi: 10.1016/j.eclinm.2023.102250. PMID: 37855026; PMCID: PMC10579289.

Tags: ACTIV-2, covid-19, Infectious Diseases, Inhaled interferon, Publications, Randomized clinical trial, SARS-CoV-2

Implementation Does Not Occur in a Vacuum: Sustaining a Comprehensive and Global Vision for HIV Research

Gianella S, Lauring A, Paredes R, Croda J, Andes D, Uhlemann AC, Chew K, Stephenson KE, Lewnard JA, John ARO, Leung DT, Clancy CJ, Chu[...]

Recurrent mutations in the stress regulator Cap1 reveal a trade-off between azole resistance and oxidative stress response in Candida albicans

Zhou X, Hilk A, Solis NV, Scott N, Zajac C, Filler SG, Selmecki A. Recurrent mutations in the stress regulator Cap1 reveal a trade-off between[...]

Author Correction: Albumin orchestrates a natural host defence mechanism against mucormycosis

Pikoulas A, Morianos I, Nidris V, Hamdy R, Intze E, López-López Á, Moran-Garrido M, Muthu V, Halabalaki M, Papaioanou V, Papadovasilaki M, Kyrmizi I, Gu[...]